1. Perez-Jeldres, T, Tyler, CJ, Boyer, JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol 2019; 10: 212.
Google Scholar | Crossref | Medline2. Sandborn, WJ, Ghosh, S, Panes, J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616–624.
Google Scholar | Crossref | Medline | ISI3. Sandborn, WJ, Su, C, Panes, J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 377: 496–497.
Google Scholar | Crossref | Medline4. Sands, BE, Armuzzi, A, Marshall, JK, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020; 51: 271–280.
Google Scholar | Crossref | Medline5. Sherman, RE, Anderson, SA, Dal Pan, GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med 2016; 375: 2293–2297.
Google Scholar | Crossref | Medline | ISI6. Ha, C, Ullman, TA, Siegel, CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10: 1002–1007.
Google Scholar | Crossref | Medline | ISI7. Rutgeerts, P, Sandborn, WJ, Feagan, BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
Google Scholar | Crossref | Medline | ISI8. Pugliese, D, Armuzzi, A. Difference in treatment outcomes between clinical trials and ‘real-life’ clinical practice: ustekinumab in ulcerative colitis. United European Gastroenterol J 2020; 8: 11–12.
Google Scholar | SAGE Journals | ISI9. Moher, D, Shamseer, L, Clarke, M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1–9.
Google Scholar | Crossref | Medline10. Shimizu, H, Fujii, T, Hibiya, S, et al. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res 2021; 19: 115–118.
Google Scholar | Crossref | Medline11. Hoffmann, P, Globig, A-M, Thomann, AK, et al. Tofacitinib in treatment-refractory moderate to severe ulcerative colitis: real-world experience from a retrospective multicenter observational study. J Clin Med 2020; 9: 2177.
Google Scholar | Crossref12. Lair-Mehiri, L, Stefanescu, C, Vaysse, T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis 2020; 52: 268–273.
Google Scholar | Crossref | Medline13. Chaparro, M, Garre, A, Mesonero, F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry. J Crohns Colitis 2021; 15: 35–42.
Google Scholar | Crossref | Medline14. Straatmijer, T, van Gennep, S, Duijvestein, M, et al. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 2021; 33: 1288–1297.
Google Scholar | Crossref | Medline15. Honap, S, Chee, D, Chapman, TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis 2020; 14: 1385–1393.
Google Scholar | Crossref | Medline16. Weisshof, R, Aharoni Golan, M, Sossenheimer, PH, et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci 2019; 64: 1945–1951.
Google Scholar | Crossref | Medline17. Stroup, DF, Berlin, JA, Morton, SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group . JAMA 2000; 283: 2008–2012.
Google Scholar | Crossref | Medline | ISI18. RC Team . R: a language and environment for statistical computing. Vienna: R Core Team, 2019.
Google Scholar19. Balduzzi, S, Rücker, G, Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019; 22: 153–160.
Google Scholar | Crossref | Medline20. Viechtbauer, W . Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1–48.
Google Scholar | Crossref | ISI21. DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
Google Scholar | Crossref | Medline22. Viechtbauer, W, Cheung, MW-L. Outlier and influence diagnostics for meta-analysis. Res Synth Methods 2010; 1: 112–125.
Google Scholar | Crossref | Medline | ISI23. Egger, M, Smith, GD, Schneider, M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
Google Scholar | Crossref | Medline24. Higgins, JPT, Thompson, SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
Google Scholar | Crossref | Medline | ISI25. Rudrapatna, VA, Glicksberg, BS, Butte, AJ. A comparison of the randomized clinical trial efficacy and real-world effectiveness of tofacitinib for the treatment of inflammatory bowel disease: a cohort study. medRxiv 2019: 19007195, http://medrxiv.org/content/early/2019/10/02/19007195.abstract
Google Scholar | Crossref26. Kolar, M, Lukas, M, Malickova, K, et al. Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice. Gastroenterol Hepatol 2020; 74: 28–34.
Google Scholar | Crossref27. Biemans, VBC, Sleutjes, JAM, de Vries, AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) Registry. Aliment Pharmacol Ther 2020; 51: 880–888.
Google Scholar | Crossref | Medline28. Deepak, P, Alayo, QA, Khatiwada, A et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2021; 19: 1592–1601.e3.
Google Scholar29. Ungaro, R, Fenster, M, Dimopoulos, C, et al. P344 real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. J Crohns Colitis 2019; 13(Suppl. 1): S274–S275.
Google Scholar | Crossref30. Higgins, JPT, Thompson, SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663–1682.
Google Scholar | Crossref | Medline | ISI31. Verstockt, B, Outtier, A, Lefrère, J, et al. P399 endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: a prospective real-life cohort. J Crohns Colitis 2020; 14(Suppl. 1): S369–S370.
Google Scholar | Crossref | Medline32. Sandborn, WJ, Panes, J, Sands, BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 2019; 50: 1068–1076.
Google Scholar | Crossref | Medline33. Sandborn, WJ, Panés, J, D’Haens, GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from Global Clinical Trials. Clin Gastroenterol Hepatol 2019; 17: 1541–1550.
Google Scholar | Crossref | Medline34. Sandborn, WJ, Su, C, Sands, BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723–1736.
Google Scholar | Crossref | Medline35. Feagan, BG, Dubinsky, M, Lukas, M, et al. Efficacy and safety of an additional 8 weeks of Tofacitinib induction therapy: results of the OCTAVE open study for Tofacitinib 8-week induction non-responders. Gastroenterology 154: S-377.
Google Scholar | Crossref36. Pfizer . Pfizer shares co-primary endpoint results from post-marketing required safety study of Xeljanz (tofacitinib) in subjects with rheumatoid arthritis (RA), https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing (2021, accessed 13 February 2021).
Google Scholar37. Cremer, A, Lobaton, T, Vieujan, S et al. P422 tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study. J Crohns Colitis 2020; 14(Suppl. 1): S384–S386.
Google Scholar38. Clark-Snustad, KD, Singla, A, Lee, SD. Su1928–tofacitinib improves clinical disease activity in a real-world population of patients with moderate-severe ulcerative colitis and Crohn’s disease. Gastroenterology 2019; 156: S-664.
Google Scholar | Crossref39. Xiao, Y, Lakatos, PL, Bourdages, R, et al. P512 efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data. J Crohns Colitis 2020; 14(Suppl. 1): S444–S445.
Google Scholar | Crossref40. Rutka, M, Farkas, K, Pigniczki, D, et al. P663 efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies. J Crohns Colitis 2020; 14(Suppl. 1): S545–S546.
Google Scholar | Crossref41. Thorlund, K, Imberger, G, Johnston, BC, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE 2012; 7: e39471.
Google Scholar | Crossref | Medline42. Verstockt, B, Van Assche, G, Vermeire, S, et al. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther 2017; 17: 31–47.
Google Scholar | Crossref | Medline43. Taxonera, C, Olivares, D, Alba, C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. Epub ahead of print 15 February 2021. DOI: 10.1093/ibd/izab011.
Google Scholar | Crossref